| Literature DB >> 32389495 |
Steph Wraith1, Raffael Nachbagauer2, Angel Balmaseda3, Daniel Stadlbauer2, Sergio Ojeda4, Arvind Rajabhathor2, Roger Lopez3, Andrea F Guglia2, Nery Sanchez4, Fatima Amanat2, Lionel Gresh5, Guillermina Kuan4, Florian Krammer6, Aubree Gordon7.
Abstract
We investigated humoral immune response to influenza A(H1N1)pdm infection and found 32 (22%) of the infected individuals identified by PCR failed to produce a ≥ 4-fold hemagglutinin inhibition assay (HAI) response; a subset of 18 (56%) produced an alternate antibody response (against full-length HA, HA stalk, or neuraminidase). These individuals had lower pre-existing HAI antibody titers and showed a pattern of milder illness. An additional subset of 14 (44%) did not produce an alternate antibody response, had higher pre-existing antibody titers against full-length & stalk HA, and were less sick. These findings demonstrate that some individuals mount an alternate antibody response to influenza infection. In order to design more broadly protective influenza vaccines it may be useful to target these alternate sites. These findings support that there are influenza cases currently being missed by solely implementing HAI assays, resulting in an underestimation of the global burden of influenza infection.Entities:
Keywords: Antibodies; Hemagglutination inhibition; Influenza; Neuraminidase
Mesh：
Substances：
Year: 2020 PMID： 32389495 PMCID： PMC7707244 DOI： 10.1016/j.vaccine.2020.04.069
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641